Source comparison
Thymosin Alpha-1 Infection Defense: Clinical Context Comparison
Severe Sepsis (ICU) 38–42% 28-day mortality 24–29% 28-day mortality (35% RRR) Restores T-cell IL-2 production suppressed by sepsis-induced immunoparalysis Strong evidence. 12 RCTs support adjunctive use within 48h of diagnosis Chronic Hepatitis B 18–22% HBeAg
This comparison does not assign a generated winner or score.
- Severe Sepsis (ICU)
- 38–42% 28-day mortality
- 24–29% 28-day mortality (35% RRR)
- Restores T-cell IL-2 production suppressed by sepsis-induced immunoparalysis
- Strong evidence. 12 RCTs support adjunctive use within 48h of diagnosis
- Chronic Hepatitis B
- 18–22% HBeAg seroconversion at 24 weeks
- 38–42% HBeAg seroconversion at 24 weeks
- Upregulates CD8+ cytotoxic response against HBV-infected hepatocytes
- Validated adjunct. Works best in patients with baseline CD4+ <400 cells/µL
- Severe COVID-19 (ICU)
- 52% mechanical ventilation rate, 18-day ICU stay
- 38% mechanical ventilation rate, 11.8-day ICU stay
- Prevents cytokine storm by modulating Th1/Th2 balance during viral peak
- Promising but context-dependent. Strongest effect in patients >60 with lymphopenia
- Post-Chemotherapy Infection
- 60–70% rate of febrile neutropenia episodes
- 35–42% rate of febrile neutropenia episodes
- Accelerates thymic recovery and neutrophil maturation post-chemotherapy
- Emerging evidence. 4 small trials show benefit but larger validation needed
- Recurrent Respiratory Infections (Elderly)
- 4.2 infections/year average
- 1.8 infections/year average with 6-month TA1 protocol
- Restores age-related thymic involution and T-cell repertoire diversity
- Preventive use supported by observational data. Not acute treatment
- The table shows where thymosin alpha-1 demonstrates measurable infection defense benefit. Sepsis and chronic viral infections have the strongest clinical validation. Post-chemotherapy and elderly preventive use show promise but need larger controlled trials before becoming standard protocols.